IDLDX.ST Neovici Holding AB (publ)

Healthcare Diagnostics & Research Stockholm Exchange
0.3300 SEK
Close of Nov 7, 2026
0.2500 0.5300
Market cap
SEK 76.0M
P/E
-
P/B
0.55x
ROE
0.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IDLDX.ST undervalued?

Graham number

The Graham number of Neovici Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neovici Holding AB (publ) fundamental analysis

No fundamental analysis for Neovici Holding AB (publ) yet.

Neovici Holding AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neovici Holding AB (publ)

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known …

Full company profile